Gene-regulating compositions and methods for improved immunotherapy

US11261428B2 · kind B2 · utility

Assignee

• KSQ Therapeutics, Inc. · US

Inventors

• Micah Benson · Cambridge, US
• Jason J. Merkin · Lexington, US
• Gregory V. Kryukov · Cambridge, US
• Solomon Martin Shenker · Cambridge, US
• Michael R. Schlabach · Cambridge, US
• Noah Jacob Tubo · Lexington, US
• James Martin Kaberna, II · Lexington, US

Key dates

• Filing date: Mar 14, 2019
• Grant date: Mar 1, 2022
• Expiry date: Oct 21, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2800/80
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.